NEW YORK – Quidel Corporation announced Wednesday that it has received Emergency Use Authorization from the US Food and Drug Administration for a rapid molecular diagnostic test for SARS-CoV-2 on the firm's benchtop Solana instrument.
Called the Solana SARS CoV-2 assay, the 25-minute test was cleared for moderately complex settings under CLIA. It uses nasopharyngeal and nasal swab specimens in viral transport media collected from patients suspected of COVID-19 infection.